US equities |
NVDA $234.41 ▲+1.54% MU $1,072.53 ▼-2.27% SPCX $158.91 ▲+7.32% TSLA $370.84 ▲+4.72% SNDK $1,719.04 ▼-3.84% STX $842.42 ▼-10.91% AMD $630.83 ▲+2.45% INTC $119.81 ▼-0.16%
FinancialContent

Nexalin Technology, Inc. - Common Stock (NQ:NXL)

5.572 -1.978 (-26.20%)
Delayed Quote Updated: 2:40 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nexalin Technology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
DarkHorse CEO Details AI Infrastructure Strategy as DRK Targets Sub-50 MW Compute Opportunity
Via AB Newswire
Topics Artificial Intelligence
News headline image
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
News headline image
Nexalin Technology Announces Reverse Stock Split
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
RedChip's Biotech Investor Conference Replays Now Available
Via ACCESS Newswire
News headline image
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
Company Designing FDA Application Amendments and U.S. Clinical Strategy Leveraging Extensive Real-World Neurostimulation Data Sets Reflecting Broad Clinical Experiences 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference
Via ACCESS Newswire
News headline image
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for... 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Receives Nasdaq Listing Status Notification
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
Four weeks of non-invasive DIFS™ neurostimulation delivers meaningful attention gains alongside objective brain imaging changes 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s disease 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
Peer-reviewed case report published in The American Journal on Addictions highlights significant clinical improvement and sustained abstinence following Nexalin’s non-invasive therapy 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
Appointment Follows Israeli Ministry of Health Approval for Nexalin’s Gen-2 SYNC Device 
From Nexalin Technology, Inc.
Via GlobeNewswire
News headline image
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a potential non-invasive therapy for cognitive... 
From Nexalin Technology, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >